AIM
EVH icon

Acropolis Investment Management’s Evolent Health EVH Stock Holding History

Acropolis Investment Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,000
Closed -$112K – 386
2025
Q4 		$112K Buy
+28,000
New +$156K 0.01% 288

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acropolis Investment Management's EVH Position: Q1 2026 in Review

Acropolis Investment Management sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 28,000 shares — an estimated $112K sold.

Acropolis Investment Management first reported a position in EVH in Q4 2025 and held it in 1 quarter. The position peaked at $112K in Q4 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Acropolis Investment Management reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
  • Acropolis Investment Management sold 28,000 Evolent Health shares in Q1 2026, an estimated $112K.
  • Acropolis Investment Management first reported a position in Evolent Health in Q4 2025 and held it in 1 quarter.
  • Acropolis Investment Management's Evolent Health position peaked at $112K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Acropolis Investment Management's 13F filing for Q1 2026, filed 9 Apr 2026.